Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Head of Genome Editing at CRISPR Therapeutics
TJ Cradick, PhD serves as Head of Genome Editing at CRISPR Therapeutics, where we are developing and optimizing transformative cures using CRISPR/Cas9. For over a decade, TJ has studied the nucleases that enable genome editing and can be used to correct genetic defects that cause diseases. In addition to work over the last 5 years on CRISPR/Cas nucleases, previous research included TALENs and Zinc Finger Nucleases (ZFNs). Many of these studies in academia and industry included measuring and improving specificity. TJ co-authored manuscripts on these nuclease families and bioinformatics web tools: ZFN-Site, PROGNOS, SAPTA and COSMID.
Prior to CRISPR Therapeutics, TJ was research faculty and Director of the Protein Engineering Facility at the Georgia Institute of Technology focussing on increasing and validating nuclease specificity.
Dr. Cradick’s undergraduate degree is from MIT, master’s degree from UCSF and PhD from the University Iowa.